BioNote, Inc. (KRX:377740)
South Korea
· Delayed Price · Currency is KRW 5,140.00
-30.00 (-0.58%)
Last updated: Apr 29, 2026, 11:51 AM KST
BioNote Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2019 |
| Operating Revenue | 118,324 | 102,780 | 90,081 | 479,657 | 622,355 | Upgrade
|
| Other Revenue | - | - | 0 | -0 | -0 | Upgrade
|
| Revenue | 118,324 | 102,780 | 90,081 | 479,657 | 622,355 | Upgrade
|
| Revenue Growth (YoY) | 15.12% | 14.10% | -81.22% | -22.93% | -1.45% | Upgrade
|
| Cost of Revenue | 52,648 | 51,807 | 101,739 | 139,186 | 110,352 | Upgrade
|
| Gross Profit | 65,675 | 50,973 | -11,659 | 340,471 | 512,003 | Upgrade
|
| Selling, General & Admin | 28,199 | 22,868 | 22,787 | 31,519 | 24,340 | Upgrade
|
| Research & Development | 16,841 | 13,577 | 13,405 | 16,138 | 11,300 | Upgrade
|
| Amortization of Goodwill & Intangibles | 1,011 | 1,005 | 858.1 | 174.51 | 44.15 | Upgrade
|
| Other Operating Expenses | 178.72 | 265.78 | 168.12 | 176.92 | 345.29 | Upgrade
|
| Operating Expenses | 48,867 | 38,756 | 35,510 | 45,062 | 43,255 | Upgrade
|
| Operating Income | 16,809 | 12,218 | -47,168 | 295,410 | 468,748 | Upgrade
|
| Interest Expense | -287.12 | -233.55 | -602.82 | -84.44 | -44.25 | Upgrade
|
| Interest & Investment Income | 14,697 | 20,059 | 24,630 | 9,715 | 873.63 | Upgrade
|
| Earnings From Equity Investments | - | 18,910 | - | -147,264 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -6,345 | 40,603 | 10,164 | 24,512 | 24,159 | Upgrade
|
| Other Non Operating Income (Expenses) | 40.43 | 1,096 | 420.84 | -296.63 | -123.11 | Upgrade
|
| EBT Excluding Unusual Items | 24,914 | 92,653 | -12,556 | 181,992 | 493,612 | Upgrade
|
| Gain (Loss) on Sale of Investments | -110,811 | -14,511 | -88,791 | 219,374 | 376,239 | Upgrade
|
| Gain (Loss) on Sale of Assets | -1,671 | 20.25 | 265.2 | 13,412 | 33.39 | Upgrade
|
| Asset Writedown | - | -4,835 | -8,409 | - | - | Upgrade
|
| Pretax Income | -87,568 | 73,327 | -109,491 | 414,778 | 869,885 | Upgrade
|
| Income Tax Expense | -70.26 | 18,065 | -88,994 | 106,980 | 193,284 | Upgrade
|
| Net Income | -87,498 | 55,261 | -20,497 | 307,798 | 676,601 | Upgrade
|
| Net Income to Common | -87,498 | 55,261 | -20,497 | 307,798 | 676,601 | Upgrade
|
| Net Income Growth | - | - | - | -54.51% | 28.09% | Upgrade
|
| Shares Outstanding (Basic) | 101 | 102 | 102 | 94 | 94 | Upgrade
|
| Shares Outstanding (Diluted) | 101 | 102 | 102 | 94 | 94 | Upgrade
|
| Shares Change (YoY) | -0.79% | -0.02% | 8.16% | 0.64% | 0.14% | Upgrade
|
| EPS (Basic) | -865.00 | 542.00 | -200.99 | 3277.21 | 7232.04 | Upgrade
|
| EPS (Diluted) | -865.00 | 542.00 | -201.00 | 3264.00 | 7222.00 | Upgrade
|
| EPS Growth | - | - | - | -54.81% | 27.91% | Upgrade
|
| Free Cash Flow | 6,270 | 47,454 | -8,156 | 206,834 | 485,966 | Upgrade
|
| Free Cash Flow Per Share | 61.99 | 465.43 | -79.98 | 2193.65 | 5186.94 | Upgrade
|
| Gross Margin | 55.51% | 49.59% | -12.94% | 70.98% | 82.27% | Upgrade
|
| Operating Margin | 14.21% | 11.89% | -52.36% | 61.59% | 75.32% | Upgrade
|
| Profit Margin | -73.95% | 53.77% | -22.75% | 64.17% | 108.72% | Upgrade
|
| Free Cash Flow Margin | 5.30% | 46.17% | -9.05% | 43.12% | 78.09% | Upgrade
|
| EBITDA | 26,036 | 20,404 | -38,962 | 301,861 | 472,854 | Upgrade
|
| EBITDA Margin | 22.00% | 19.85% | -43.25% | 62.93% | 75.98% | Upgrade
|
| D&A For EBITDA | 9,227 | 8,186 | 8,206 | 6,451 | 4,106 | Upgrade
|
| EBIT | 16,809 | 12,218 | -47,168 | 295,410 | 468,748 | Upgrade
|
| EBIT Margin | 14.21% | 11.89% | -52.36% | 61.59% | 75.32% | Upgrade
|
| Effective Tax Rate | - | 24.64% | - | 25.79% | 22.22% | Upgrade
|
| Advertising Expenses | 3,687 | 2,422 | 2,414 | 2,332 | 1,063 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.